F-star Therapeutics Inc Stock, NASDAQ:FSTX
Eddeva B920, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3AT
United States of America
Number of Employees: 75
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company is headquartered in Cambridge, the United Kingdom.